Risperidone for attention-deficit hyperactivity disorder in people with intellectual disabilities

Area of Science:

• Neuroscience
• Psychiatry
• Clinical Psychology

Background:

• Attention deficit hyperactivity disorder (ADHD) is increasingly recognized in individuals with intellectual disabilities (ID).
• Current treatment options for ADHD in people with ID are not widely tested, and evidence for risperidone's effectiveness is unclear.
• This highlights a significant gap in evidence-based care for this vulnerable population.

Purpose of the Study:

• To systematically review the existing randomized controlled trials (RCTs) evaluating the effectiveness of risperidone for treating ADHD in individuals with intellectual disabilities.
• To assess the quality and applicability of current research on risperidone for ADHD in the context of ID.

Main Methods:

• A comprehensive literature search was conducted across multiple databases (MEDLINE, PsycINFO, EMBASE, etc.) and clinical trial registries up to February 2009.
• Searches included terms for ADHD and ID, and pharmaceutical companies and experts were contacted.
• Inclusion criteria focused on RCTs of risperidone for ADHD in individuals with ID, regardless of publication status or language.

Main Results:

• Eleven studies were identified and reviewed.
• However, none of the identified studies met the inclusion criteria for randomized controlled trials.
• Consequently, no data were collected or analyzed due to the lack of suitable studies.

Conclusions:

• There is a lack of high-quality evidence from RCTs to support the use of risperidone for treating ADHD in individuals with ID.
• Current prescribing practices rely on limited open-label studies or extrapolations from research in other populations (e.g., autism), which may not be directly applicable.
• Urgent research is needed to establish the effectiveness and tolerability of treatments for ADHD in people with ID.